VIR vs AURA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
VIR Captures Institutional Edge (2โ2 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Vir Biotechnology, Inc. Common Stock (VIR) driven by superior Valuation, Momentum & Technical while AURA counters with relative strength in Growth & Margin, Options & Structure. Fundamentally, VIR trades at 4.3x Forward P/E with -70.2% operating margin (+19582.5% YoY revenue) versus AURA at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, VIR sits in BREAKDOWN (6th %ile IV; Dealer Gamma Walls on Pro) against AURA sits in CONSOLIDATION (22nd %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | VIR | AURA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $2.1B | $728.6M | Larger Scale | VIR |
| Trailing P/E Ratio Valuation | 4.3x | N/M | Lower Multiple | VIR |
| Forward P/E Ratio Valuation | 4.3x | N/M | Lower Multiple | VIR |
| Revenue Growth (YoY) Growth | +19582.5% | +0.0% | Higher Growth | VIR |
| Operating Margin (TTM) Profitability | -70.2% | 0.0% | Higher Margin | AURA |
| Net Profit Margin Profitability | -61.0% | 0.0% | Higher Margin | AURA |
| Return on Equity (ROE) Capital Efficiency | -21.8% | -61.7% | Higher ROE | VIR |
| 52-Week Range Position Momentum | 49% ($5โ$14) | 52% ($5โ$10) | Stronger Trend | AURA |
| Beta / 30D Volatility Risk Regime | 1.71ฮฒ ยท 102% Vol | 0.92ฮฒ ยท 75% Vol | Lower Realized Risk | AURA |
| Unified Institutional Score Composite Signal | 41.6 / 100 (SELL) | 28.8 / 100 (SELL) | Higher Composite | VIR |